This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nathan's Most Recent Article

A Buysider's Preview of Biotech's Biggest Conference

01/02/13 - 07:00 AM EST

Nate Sadeghi breaks down next week's J.P. Morgan Healthcare Conference.

read more >

Other Articles by Nathan

Free Reports

Rethinking Idenix Pharma in Wake of Bristol's Hep C Blow Up

08/06/12 - 07:00 AM EDT

The two Hep C drugs are similar enough chemically to warrant caution.

read more >
Gilead Sciences Firing On All Cylinders

07/30/12 - 07:00 AM EDT

Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.

read more >
The Health Care Short Sales That Never Fit

07/23/12 - 07:00 AM EDT

Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.

read more >
Eli Lilly, Verastem and the Defenders of Shareholder Value

07/16/12 - 07:07 AM EDT

TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.

read more >
Onyx Pharma Must Start Delivering Profits

07/10/12 - 08:10 AM EDT

With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.

read more >
ObamaCare Upheld: Health Care Stock Winners and Losers

06/28/12 - 11:38 AM EDT

TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.

read more >
Arena Pharma And The Fat Lady's Song

06/25/12 - 11:13 AM EDT

Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.

read more >
Alkermes Needs to Build on Drug Delivery Success

06/18/12 - 07:00 AM EDT

An undervalued stock could move higher if Alkermes continues to grow through acquisitions.

read more >
A Reckoning Approaches: Supreme Court and Obama's Healthcare Reform Law

06/11/12 - 07:09 AM EDT

Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.

read more >
Bad Romance: Glaxo's Brutal Courtship of Human Genome Sciences

06/04/12 - 07:45 AM EDT

Contributor Nathan Sadeghi-Nejad offers tips to Glaxo's CEO on how to woo the stubborn HGSI into marriage.

read more >
Page 3 of 5
Top Rated Stocks Top Rated Funds Top Rated ETFs